Actions
Pages
Subscribe for newsletter
Stories
Hong Kong's Insilico Medicine teams up with New Zealand's SRW Laboratories to develop AI-driven longevity nutraceuticals, leveraging Insilico's Pharma.AI platform to expedite the discovery of natural compounds that extend healthspan.
Aging populations are on the rise, set to reach 2.1 billion by 2050, with a threefold increase in those aged 80 or older. Insilico and SRW's collaboration uses AI tech to address age-related health issues with a focus on natural wellness to sustain a longer, better quality of life.
“We’ve been utilising our technology to increase output in the pharmaceutical space for years, but this is the first time we’re turning our attention to the natural supplement sector. We’re excited to help SRW make huge strides in analysing which compounds are the most effective and bring them to market. Extending the number of healthy years in a person’s life is a very motivating mission,” said Alex Zhavoronkov, PhD, co-CEO and founder of Insilico.
The partnership anticipates unveiling its first AI-assisted product suite in 2024.
By merging biotech, AI and natural sciences together, this method aims to target cellular aging rather than treating symptoms. The integration of AI into nutraceuticals reflects a holistic health approach.
While the promise of AI in drug discovery is immense, there remains a cautious outlook due to previous setbacks in AI-generated drugs, highlighting the need for successful clinical outcomes to fully validate this approach.
Story
Lockheed Martin, leading US defense security company, is set to launch a satellite into low Earth orbit in 2024, as part of their space-based 5G network initiative. This project aims to enhance global connectivity and advance military communication capabilities.
This advancement integrates space technology with terrestrial networks to meet the rising demand for reliable, high-speed communication in remote areas. This move highlights the importance of space assets in global communications.
“Space will be the major enabler of being able to use 5G across different platforms. “It’s been slower to get traction because of the cost, and you’ve got to have standards to be able to make this work across the industry," said Joe Rickers, VP of connectivity, transport and access at Lockheed Martin. "It’s really starting to come together. We’ve still got a ways to go but we’ve seen a lot of progress.”
This launch could lead to increased adoption of space-based 5G networks, opening new opportunities in both civilian and defense sectors.
Is this US defense darling trying to give Space X’s Starlink a run for their money by moving in to the satellite internet space? This project also straddles the line between defense and commercial interests, raising questions about the balance of security and accessibility in global communications.
Story
Genentech, a Roche biotech subsidiary, is partnering with Nvidia in a multi-year deal to leverage artificial intelligence for faster, more efficient drug development. By leveraging AI research, Genentech hopes to speed up drug discovery and simultaneously improve Nvidia’s own drug discovery software, BioNemo.
Biotech companies are relying on AI increasingly to expedite the timeline from drug discovery to disease target and human clinical trials. The ability to deliver a new, critical drug to the market is crucial for saving lives and giving pharmaceutical companies a competitive edge.
“Our collaboration with NVIDIA builds on our long history of successfully inventing and deploying technology in ways that were not initially apparent to others,” said Aviv Regev, executive vice president and head of Genentech Research & Early Development (gRED).
This partnership involves the exchange of expertise between the two companies, both top in their fields of AI and biotech research. Nvidia’s venture arm has invested in other biotech startups so these types of collaborations aren’t slowing down any time soon.
Nvidia is known for their advanced computing chips but now has extended their capabilities to imaging and claim they can predict protein structures and screen small molecules accurately and quickly. This raises questions about the implications of AI in medicine and how it can affect the regulatory landscape.
Genentech's venture into AI includes a $12 billion collaboration with Recursion in 2021. This partnership targets over 40 programs in neuroscience and oncology, further highlighting Genentech's steady trajectory towards AI-driven innovation in pharmaceuticals.
Story
Innovators
Scroll
Open
Close